Adipotide
aka FTPP
Mechanism
Adipotide (FTPP) is a chimeric peptidomimetic developed in the Arap/Pasqualini lab (originally at MD Anderson) that couples a 9-residue homing motif (CKGGRAKDC) — isolated by in vivo phage display as a ligand for prohibitin on white-adipose-tissue vasculature — to the D-amino-acid pro-apoptotic domain D(KLAKLAK)2. It is an experimental research compound, NOT FDA-approved for any indication. A clinical-development program in prostate-cancer-associated obesity reached early-phase testing and was ultimately discontinued.
Identification
| CAS number | 859216-15-2 |
|---|---|
| Molecular formula | C111H206N36O28S2 |
| Sequence | CKGGRAKDCGGKLAKLAKKLAKLAK |
| Typical dose | 0.10–0.75 mg/kg/day subcutaneous (primate research); human dosing not established |
| Half-life | ~2–4 hours (plasma, preclinical data) |
Vendors selling Adipotide
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Orbitrex Peptides | 10 mg | $165.00 | — | 95 |
| Peptide Tech | 5 mg | $69.99 | — | 94 |
| Qihang Peptide | — | — | — | 87 |
| Peptidegurus | 10 mg | — | — | 84 |
| Peptidegurus | 10 mg | — | — | 84 |
| Certified Peptides | 10 mg | $165.00 | — | 62 |
| Peptiatlas | — | — | — | 51 |
| HongDa Peptide | — | $86.00 | — | 43 |
| zztai Peptide Ltd | — | — | — | 43 |
| MJT peptides | 5 mg | $173.00 | — | 39 |
| Biotech Peptides | 10 mg | $77.00 | — | — |
| Core Peptides | 10 mg | $78.00 | — | — |
| Genetic Peptide | 5 mg | $45.00 | — | — |
Research
Clinical consensus statements have been issued for various adipose tissues (ATs), particularly regarding the diagnostic value of epicardial AT (EAT) and perivascular AT (PVAT) in cardiovascular disease.
source →Prohibitins are the central regulatory element of cellular homeostasis, especially by modulating the response at different levels: Nucleus, mitochondria and membranes.
source →The world scenario has undergone a nutritional transition in which some countries have left the reality of malnutrition and now face an epidemic of excess body weight. Researchers have been looking for strategies to reverse this situation. Peptides and proteins stand out as promising molecules with anti-obesity action.
source →Peptides are at the cutting edge of contemporary research for new potent, selective, and safe therapeutical agents. Their rise has reshaped the pharmaceutical landscape, providing solutions to challenges that traditional small molecules often cannot address.
source →The function of prohibitin-1 (PHB1) in adipocyte mitochondrial respiration, adaptive thermogenesis, and long-chain fatty acid (LCFA) metabolism has been reported. While intracellular PHB1 expression is ubiquitous, cell surface PHB1 localization is selective for adipocytes and endothelial cells of adipose tissue.
source →A decline in mitochondrial function has long been associated with age-related health decline. Several lines of evidence suggest that interventions that stimulate mitochondrial autophagy (mitophagy) can slow aging and prolong healthy lifespan.
source →Over the last three decades, the scaffold proteins prohibitins-1 and -2 (PHB1/2) have emerged as key signaling proteins regulating a myriad of signaling pathways in health and diseases.
source →Human obesity has become a global health epidemic, with few safe and effective pharmacological therapies currently available. The systemic loss of ovarian estradiol (E2) in women after menopause greatly increases the risk of obesity and metabolic dysfunction, revealing the critical role of E2 in this setting.
source →Antiangiogenesis has been the focus of a new strategy for the treatment of obesity.
source →Prohibitins (PHBs) are scaffold proteins that modulate many signaling pathways controlling cell survival, metabolism, and inflammation. Several drugs that target PHBs have been identified and evaluated for various clinical applications.
source →A study reporting that a peptidomimetic adipotide reduces weight loss in obese monkeys by inducing apoptosis of blood vessels surrounding white adipose tissue may instead reflect a direct effect of adipotide on food consumption.
source →Obesity, defined as body mass index greater than 30, is a leading cause of morbidity and mortality and a financial burden worldwide. Despite significant efforts in the past decade, very few drugs have been successfully developed for the treatment of obese patients.
source →